DEFA14A: Unicycive Therapeutics Updates Beneficial Ownership Ahead of June 2025 Annual Meeting
Proxy Statement Amendment
Unicycive Therapeutics files a second amendment to its proxy statement, updating the beneficial ownership table in advance of its annual meeting on June 9, 2025.
Summary
- Unicycive Therapeutics has filed a second amendment and supplement to its proxy statement related to the annual meeting of stockholders to be held on June 9, 2025.
- The amendment updates the beneficial ownership table, providing details on the ownership of common stock, Series A Preferred Stock, and Series B Preferred Stock as of the Record Date.
- The percentage ownership of common stock is based on 120,629,281 shares outstanding on the Record Date.
- The percentage ownership of Series A-2 Prime Preferred Stock is based on 5,464.21 shares outstanding, and Series B-2 Preferred Stock is based on 3,000 shares outstanding.
- The filing details the number of shares beneficially owned by directors, named executive officers, and significant stockholders (those owning more than 5%).
- It includes shares held outright as well as those issuable upon exercise of options or conversion of preferred stock within 60 days of the Record Date.
Sentiment
Score: 5
Explanation: The document is a factual update on share ownership, with no inherent positive or negative sentiment.
Industry Context
This filing is a routine part of corporate governance, ensuring transparency for shareholders regarding ownership structure, which is particularly important for companies with complex capital structures involving multiple classes of stock and convertible securities.
Stakeholder Impact
- Shareholders are provided with updated information on the ownership structure of the company.
- This information can influence shareholder decisions regarding voting and investment.
Next Steps
- Stockholders should review the updated proxy statement before voting.
- Stockholders should submit their proxies or vote at the Annual Meeting on June 9, 2025.
Key Dates
| Date | Description |
|---|---|
| April 30, 2025 | Unicycive filed its definitive proxy statement with the SEC. |
| May 7, 2025 | The Company filed an Amendment and Supplement to the Proxy Statement (the First Amendment and Supplement). |
| June 9, 2025 | Date of the Annual Meeting of Stockholders. |
Keywords
beneficial ownership, proxy statement, Unicycive Therapeutics, annual meeting, stockholders, common stock, preferred stock, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.